A nationwide causal mediation analysis of survival following ST-elevation myocardial infarction

Tatendashe Bernadette Dondo, Marlous Hall, Theresa Munyombwe, Chris Wilkinson, Mohammad E Yadegarfar, Adam Timmis, Philip D Batin, Tomas Jernberg, Keith Aa Fox, Chris P Gale, Tatendashe Bernadette Dondo, Marlous Hall, Theresa Munyombwe, Chris Wilkinson, Mohammad E Yadegarfar, Adam Timmis, Philip D Batin, Tomas Jernberg, Keith Aa Fox, Chris P Gale

Abstract

Objective: International studies report a decline in mortality following ST-elevation myocardial infarction (STEMI). The extent to which the observed improvements in STEMI survival are explained by temporal changes in patient characteristics and utilisation of treatments is unknown.

Methods: Cohort study using national registry data from the Myocardial Ischaemia National Audit Project between first January 2004 and 30th June 2013. 232 353 survivors of hospitalisation with STEMI as recorded in 247 hospitals in England and Wales. Flexible parametric survival modelling and causal mediation analysis were used to estimate the relative contribution of temporal changes in treatments and patient characteristics on improved STEMI survival.

Results: Over the study period, unadjusted survival at 6 months and 1 year improved by 0.9% and 1.0% on average per year (HR: 0.991, 95% CI: 0.988 to 0.994 and HR: 0.990, 95% CI: 0.987 to 0.993, respectively). The uptake of primary percutaneous coronary intervention (PCI) (HR: 1.025, 95% CI: 1.021 to 1.028) and increased prescription of P2Y12 inhibitors (HR: 1.035, 95% CI: 1.031 to 1.039) were significantly associated with improvements in 1-year survival. Primary PCI explained 16.8% (95% CI: 10.8% to 31.6%) and 13.2% (9.2% to 21.9%) of the temporal survival improvements at 6 months and 1 year, respectively, whereas P2Y12 inhibitor prescription explained 5.3% (3.6% to 8.8%) of the temporal improvements at 6 months but not at 1 year.

Conclusions: For STEMI in England and Wales, improvements in survival between 2004 and 2013 were significantly explained by the uptake of primary PCI and increased use of P2Y12 inhibitors at 6 months and primary PCI only at 1 year.

Trial registration number: NCT03749694.

Keywords: acute coronary syndromes; acute myocardial infarction; electronic medical records; epidemiology; quality and outcomes of care.

Conflict of interest statement

Competing interests: CPG reports personal fees and non-financial support from AstraZeneca, non-financial support from BMS-Pfizer, personal fees from Bayer, personal fees from Novartis, personal fees from Vifor Pharma, outside the submitted work. KAAF reports grants and personal fees from Bayer/Janssen, grants from AstraZeneca, personal fees from Sanofi/Regeneron, personal fees from Verseon, outside the submitted work.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.

Figures

Figure 1
Figure 1
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) diagram showing the derivation of the analytical cohort from the Myocardial Ischaemia National Audit Project dataset.
Figure 2
Figure 2
Temporal trends of comorbidities and risk factors, per month, 2004–2013.
Figure 3
Figure 3
Use of pharmacological therapies at hospital discharge, thrombolysis and primary percutaneous coronary intervention per month, 2004–2013.
Figure 4
Figure 4
Crude all-cause mortality at 6-month and 1-year following hospital discharge, per month, 2004–2013.

References

    1. Fox KAA, Steg PG, Eagle KA, et al. . Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA 2007;297:1892–900. 10.1001/jama.297.17.1892
    1. Hall M, Laut K, Dondo TB, et al. . Patient and hospital determinants of primary percutaneous coronary intervention in England, 2003–2013. Heart 2016;102:313–9. 10.1136/heartjnl-2015-308616
    1. Puymirat E, et al. Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction. JAMA 2012;308:998–1006. 10.1001/2012.jama.11348
    1. Szummer K, Wallentin L, Lindhagen L, et al. . Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995–2014. Eur Heart J 2017;38:3056–65. 10.1093/eurheartj/ehx515
    1. Eagle KA, Nallamothu BK, Mehta RH, et al. . Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got a long way to go. Eur Heart J 2008;29:609–17. 10.1093/eurheartj/ehn069
    1. Herrett E, Smeeth L, Walker L, et al. . The myocardial ischaemia national audit project (MINAP). Heart 2010;96:1264–7. 10.1136/hrt.2009.192328
    1. Wilkinson C, Weston C, Timmis A, et al. . Cohort profile: the myocardial ischaemia national audit project (MINAP). Eur Heart J Qual Care Clin Outcomes 2019:qcz052 10.1093/ehjqcco/qcz052
    1. Thygesen K, Alpert JS, Jaffe AS, et al. . Third universal definition of myocardial infarction. Circulation 2012;126:2020–35. 10.1161/CIR.0b013e31826e1058
    1. Royston P, Lambert PC. Flexible parametric survival analysis using Stata: beyond the Cox model. StataCorp LP, College Station, Texas: Stata Press, 2011.
    1. Ibanez B, James S, Agewall S, et al. . Esc guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevationThe Task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of cardiology (ESC). Eur Heart J 2017;2017.
    1. West RM, Cattle BA, Bouyssie M, et al. . Impact of hospital proportion and volume on primary percutaneous coronary intervention performance in England and Wales. Eur Heart J 2011;32:706–11. 10.1093/eurheartj/ehq476
    1. Zijlstra F, Hoorntje JCA, de Boer M-J, et al. . Long-Term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1999;341:1413–9. 10.1056/NEJM199911043411901
    1. Andersen HR, Nielsen TT, Rasmussen K, et al. . A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003;349:733–42. 10.1056/NEJMoa025142
    1. Gale C, Allan V, Cattle B, et al. . Trends in hospital treatments, including revascularisation, following acute myocardial infarction, 2003–2010: a multilevel and relative survival analysis for the National Institute for cardiovascular outcomes research (NICOR).. Heart 2014.
    1. Townsend N, Wilson L, Bhatnagar P, et al. . Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J 2016;37:3232–45. 10.1093/eurheartj/ehw334
    1. Motovska Z, Bhatt DL. 12 months of DAPT after acute coronary syndrome still beats 6 months. The Lancet 2018;391:1240–2. 10.1016/S0140-6736(18)30612-3
    1. Hahn J-Y, Song YB, Oh J-H, et al. . 6-Month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. The Lancet 2018;391:1274–84. 10.1016/S0140-6736(18)30493-8
    1. Kedhi E, Fabris E, van der Ent M, et al. . Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial. BMJ 2018;363 10.1136/bmj.k3793
    1. Wilson SJ, Newby DE, Dawson D, et al. . Duration of dual antiplatelet therapy in acute coronary syndrome. Heart 2017;103:573–80. 10.1136/heartjnl-2016-309871
    1. Laut KG, Gale CP, Lash TL, et al. . Determinants and patterns of utilization of primary percutaneous coronary intervention across 12 European countries: 2003–2008. Int J Cardiol 2013;168:2745–53. 10.1016/j.ijcard.2013.03.085
    1. Laut KG, Gale CP, Pedersen AB, et al. . Persistent geographical disparities in the use of primary percutaneous coronary intervention in 120 European regions: exploring the variation. EuroIntervention 2013;9:469–76. 10.4244/EIJV9I4A76
    1. Bebb OJ, Hall M, Gale CP. Why report outcomes when process measures will suffice? Oxford University Press, 2016.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅